{"abstract":"The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (PRA).","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/03/16/2021-05330.html","cfr_references":[],"citation":"86 FR 14440","comment_url":null,"comments_close_on":"2021-04-15","correction_of":null,"corrections":[],"dates":"Submit written comments (including recommendations) on the collection of information by April 15, 2021.","disposition_notes":null,"docket_ids":["Docket No. FDA-2019-N-5666"],"dockets":[{"supporting_documents":[{"title":"Docket No FDA-2019-N-5666 Ref 2 RE: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Empirical Study of Promotional Implications of Proprietary Prescription Drug Names","document_id":"FDA-2019-N-5666-0011"},{"title":"Docket No FDA-2019-N-5666 Ref 1 re: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Empirical Study of Promotional Implications of Proprietary Prescription Drug Names","document_id":"FDA-2019-N-5666-0010"}],"agency_name":"FDA","documents":[{"comment_count":0,"comment_start_date":"2021-03-16","updated_at":"2023-02-28T22:35:28.459-05:00","comment_url":"https://www.regulations.gov/commenton/FDA-2019-N-5666-0009","allow_late_comments":null,"id":"FDA-2019-N-5666-0009","comment_end_date":null,"regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":2,"id":"FDA-2019-N-5666","title":"Agency Information Collection Activities; Proposed Collection; Comment Request; Empirical Study of Promotional Implications of Proprietary Prescription Drug Names"}],"document_number":"2021-05330","effective_on":null,"end_page":14445,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/03/16/2021-05330.xml","html_url":"https://www.federalregister.gov/documents/2021/03/16/2021-05330/agency-information-collection-activities-submission-for-office-of-management-and-budget-review","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-05330?publication_date=2021-03-16","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-03-16/2021-05330/mods.xml","not_received_for_publication":null,"page_length":6,"page_views":{"count":412,"last_updated":"2026-04-24 16:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-03-16/pdf/2021-05330.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-05330.pdf?1615812317","publication_date":"2021-03-16","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/03/16/2021-05330.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[{"title":"Docket No FDA-2019-N-5666 Ref 2 RE: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Empirical Study of Promotional Implications of Proprietary Prescription Drug Names","document_id":"FDA-2019-N-5666-0011"},{"title":"Docket No FDA-2019-N-5666 Ref 1 re: Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Empirical Study of Promotional Implications of Proprietary Prescription Drug Names","document_id":"FDA-2019-N-5666-0010"}],"comments_count":0,"agency_id":"FDA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=FDA-2019-N-5666","supporting_documents_count":2,"docket_id":"FDA-2019-N-5666","document_id":"FDA-2019-N-5666-0009","regulation_id_number":null,"title":"Agency Information Collection Activities; Proposed Collection; Comment Request; Empirical Study of Promotional Implications of Proprietary Prescription Drug Names","checked_regulationsdotgov_at":"2023-03-01T03:35:27Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":14440,"subtype":null,"title":"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Empirical Study of Promotional Implications of Proprietary Prescription Drug Names","toc_doc":"Empirical Study of Promotional Implications of Proprietary Prescription Drug Names","toc_subject":"Agency Information Collection Activities; Proposals, Submissions, and Approvals:\n","topics":[],"type":"Notice","volume":86}